Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Go back to Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD| SUPERNUS PHARM (NASDAQ: SUPN) | Delayed: 42.78 +0.78 (1.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.00 | 52 Week High | $26.84 | |||
| Open | $42.00 | 52 Week Low | $9.51 | |||
| Day High | $42.97 | P/E | N/A | |||
| Day Low | $41.68 | EPS | $-2.62 | |||
| Volume | 635,722 | |||||
